COMPOSÉS AYANT UNE ACTIVITÉ INHIBITRICE DE CASPASE, AGENT PHARMACEUTIQUE LES CONTENANT POUR LE TRAITEMENT OU LA PRÉVENTION DES SYMPTÔMES, TROUBLES OU MALADIES DE L'ENDOTHÉLIUM CORNÉEN, ET APPLICATION DUDIT AGENT PHARMACEUTIQUE
The present invention provides a composition for treating or preventing corneal endothelial symptoms, disorders, or diseases that are attributed to TGF-β signaling in corneal endothelial cells. Provided by the present invention is a composition that includes a compound and that is for treating or preventing endothelial symptoms, disorders, or diseases, wherein, when the compound comes into contact with immortalized cells of Fuchs' corneal endothelial dystrophy, (i) said immortalized cells exhibit a cell survival rate (%) of approximately 90% or more after being cultured for 24-28 hours in Dulbecco's modified Eagle medium (DMEM) + 2% fetal bovine serum (FBS) + 1% penicillin/streptomycin (P/S), and (ii) the ratio of caspase 3/7 activity (%) in the presence of TGF-β with respect to said cellular survival rate (%) is at most 0.8 after being cultured for 24-28 hours in Dulbecco's modified Eagle medium (DMEM) + 2% fetal bovine serum (FBS) + 1% penicillin/streptomycin (P/S).
